An observational study in Hypertension, Pulmonary, sponsored by GlaxoSmithKline. Completed at 113 sites in 15 countries. Per ClinicalTrials.gov, last updated 2017-03-23.
Sponsored by GlaxoSmithKline · Observational
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
1,105 studies on the registry are indexed under Hypertension, Pulmonary; 234 are open to participants now.
This study's enrollment of 800 is above the median of 116 across 386 observational studies indexed under Hypertension, Pulmonary.
Browse Hypertension, Pulmonary studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
subjects who have been prescribed ambrisentan for a medically appropriate use. (See approved product label e.g. Summary of Product Characteristics. )
subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label)
ambrisentan prescribed subjects
Drug: ambrisentan
ambrisentan
safety monitoring
safety monitoring
Showing the first 100 of 113 sites across 15 countries.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline